欧盟批准-话题@MedSci

#欧盟批准#

135篇内容 | 2711人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1589969, encodeId=a388158996931, content=<a href='/topic/show?id=2d1c63118e9' target=_blank style='color:#2F92EE;'>#欧盟批准#</a>, objectTitle=丙肝重大里程碑！吉利德全球泛基因型丙肝鸡尾酒Epclusa获美国和欧盟批准！, objectType=article, longId=72482, objectId=cf02e24823e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cf02e24823e, replyNumber=0, likeNumber=47, createdTime=2016-07-12, rootId=0, userName=chenwq14, userId=f0d617780998, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cf02e24823e, moduleTitle=丙肝重大里程碑！吉利德全球泛基因型丙肝鸡尾酒Epclusa获美国和欧盟批准！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cf02e24823e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1589968, encodeId=e615158996892, content=<a href='/topic/show?id=2d1c63118e9' target=_blank style='color:#2F92EE;'>#欧盟批准#</a>, objectTitle=欧盟批准武田抗癌药Adcetris用于霍奇金淋巴瘤患者干细胞移植后的巩固治疗, objectType=article, longId=72295, objectId=f93de22957a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f93de22957a, replyNumber=0, likeNumber=72, createdTime=2016-07-09, rootId=0, userName=chenwq14, userId=f0d617780998, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f93de22957a, moduleTitle=欧盟批准武田抗癌药Adcetris用于霍奇金淋巴瘤患者干细胞移植后的巩固治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f93de22957a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1589967, encodeId=163a158996ea6, content=<a href='/topic/show?id=2d1c63118e9' target=_blank style='color:#2F92EE;'>#欧盟批准#</a>, objectTitle=喜讯！百健和艾伯维每月一次皮下注射多发性硬化症药物Zinbryta获欧盟批准, objectType=article, longId=72275, objectId=7697e227519, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7697e227519, replyNumber=0, likeNumber=69, createdTime=2016-07-09, rootId=0, userName=chenwq14, userId=f0d617780998, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7697e227519, moduleTitle=喜讯！百健和艾伯维每月一次皮下注射多发性硬化症药物Zinbryta获欧盟批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7697e227519)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1589966, encodeId=1322158996676, content=<a href='/topic/show?id=2d1c63118e9' target=_blank style='color:#2F92EE;'>#欧盟批准#</a>, objectTitle=第6个适应症！欧盟批准强生重磅抗炎药Simponi治疗多关节型幼年特发性关节炎（pJIA）, objectType=article, longId=72017, objectId=9ab1e20172f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9ab1e20172f, replyNumber=0, likeNumber=0, createdTime=2016-07-05, rootId=0, userName=chenwq14, userId=f0d617780998, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9ab1e20172f, moduleTitle=第6个适应症！欧盟批准强生重磅抗炎药Simponi治疗多关节型幼年特发性关节炎（pJIA）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9ab1e20172f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1589965, encodeId=117a15899655c, content=<a href='/topic/show?id=2d1c63118e9' target=_blank style='color:#2F92EE;'>#欧盟批准#</a>, objectTitle=喜讯！欧盟批准阿斯利康新型抗生素Zavicefta（CAZ-AVI），治疗严重细菌性感染, objectType=article, longId=71848, objectId=ac88e1848fb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ac88e1848fb, replyNumber=0, likeNumber=60, createdTime=2016-07-01, rootId=0, userName=chenwq14, userId=f0d617780998, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ac88e1848fb, moduleTitle=喜讯！欧盟批准阿斯利康新型抗生素Zavicefta（CAZ-AVI），治疗严重细菌性感染, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ac88e1848fb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1589963, encodeId=a9c31589963dd, content=<a href='/topic/show?id=2d1c63118e9' target=_blank style='color:#2F92EE;'>#欧盟批准#</a>, objectTitle=诺华Afinitor获欧盟批准治疗非功能性胃肠道和肺部神经内分泌肿瘤（NET）, objectType=article, longId=70023, objectId=a5f0e00232a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a5f0e00232a, replyNumber=0, likeNumber=80, createdTime=2016-06-07, rootId=0, userName=chenwq14, userId=f0d617780998, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a5f0e00232a, moduleTitle=诺华Afinitor获欧盟批准治疗非功能性胃肠道和肺部神经内分泌肿瘤（NET）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a5f0e00232a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1589964, encodeId=6f221589964b5, content=<a href='/topic/show?id=2d1c63118e9' target=_blank style='color:#2F92EE;'>#欧盟批准#</a>, objectTitle=第5个适应症！欧盟批准艾伯维突破性抗癌药Imbruvica一线治疗慢性淋巴细胞白血病（CLL）, objectType=article, longId=70030, objectId=0f9ae003001, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0f9ae003001, replyNumber=0, likeNumber=86, createdTime=2016-06-07, rootId=0, userName=chenwq14, userId=f0d617780998, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0f9ae003001, moduleTitle=第5个适应症！欧盟批准艾伯维突破性抗癌药Imbruvica一线治疗慢性淋巴细胞白血病（CLL）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0f9ae003001)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1589960, encodeId=26e515899601d, content=<a href='/topic/show?id=2d1c63118e9' target=_blank style='color:#2F92EE;'>#欧盟批准#</a>, objectTitle=葛兰素史克用于治疗儿童免疫疾病的基因药获欧盟批准, objectType=article, longId=70010, objectId=6a3fe001025, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6a3fe001025, replyNumber=0, likeNumber=73, createdTime=2016-06-07, rootId=0, userName=chenwq14, userId=f0d617780998, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6a3fe001025, moduleTitle=葛兰素史克用于治疗儿童免疫疾病的基因药获欧盟批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6a3fe001025)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1589961, encodeId=e0231589961d5, content=<a href='/topic/show?id=2d1c63118e9' target=_blank style='color:#2F92EE;'>#欧盟批准#</a>, objectTitle=基因治疗领域里程碑事件：欧盟批准制药巨头GSK的基因疗法上市, objectType=article, longId=70012, objectId=48a1e001297, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=48a1e001297, replyNumber=0, likeNumber=71, createdTime=2016-06-07, rootId=0, userName=chenwq14, userId=f0d617780998, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=48a1e001297, moduleTitle=基因治疗领域里程碑事件：欧盟批准制药巨头GSK的基因疗法上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=48a1e001297)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1589962, encodeId=30db158996204, content=<a href='/topic/show?id=2d1c63118e9' target=_blank style='color:#2F92EE;'>#欧盟批准#</a>, objectTitle=基因治疗新篇章！葛兰素史克干细胞基因疗法Strimvelis获欧盟批准治疗ADA-SCID, objectType=article, longId=70013, objectId=d881e0013dd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d881e0013dd, replyNumber=0, likeNumber=125, createdTime=2016-06-07, rootId=0, userName=chenwq14, userId=f0d617780998, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d881e0013dd, moduleTitle=基因治疗新篇章！葛兰素史克干细胞基因疗法Strimvelis获欧盟批准治疗ADA-SCID, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d881e0013dd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1589959, encodeId=32bc158995966, content=<a href='/topic/show?id=2d1c63118e9' target=_blank style='color:#2F92EE;'>#欧盟批准#</a>, objectTitle=多发性骨髓瘤药物daratumumab获欧盟批准, objectType=article, longId=69407, objectId=3d486940e33, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3d486940e33, replyNumber=0, likeNumber=73, createdTime=2016-05-30, rootId=0, userName=chenwq14, userId=f0d617780998, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3d486940e33, moduleTitle=多发性骨髓瘤药物daratumumab获欧盟批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3d486940e33)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1589957, encodeId=decd158995ee8, content=<a href='/topic/show?id=2d1c63118e9' target=_blank style='color:#2F92EE;'>#欧盟批准#</a>, objectTitle=百健/Sobi长效B型血液病新药Alprolix（rFIXFc）获欧盟批准, objectType=article, longId=68858, objectId=128268858d8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=128268858d8, replyNumber=0, likeNumber=67, createdTime=2016-05-23, rootId=0, userName=chenwq14, userId=f0d617780998, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=128268858d8, moduleTitle=百健/Sobi长效B型血液病新药Alprolix（rFIXFc）获欧盟批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=128268858d8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1589958, encodeId=dfa0158995867, content=<a href='/topic/show?id=2d1c63118e9' target=_blank style='color:#2F92EE;'>#欧盟批准#</a>, objectTitle=Actelion肺动脉高压药物Uptravi获欧盟批准，扩大适应症范围, objectType=article, longId=68861, objectId=b99368861fc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b99368861fc, replyNumber=0, likeNumber=96, createdTime=2016-05-23, rootId=0, userName=chenwq14, userId=f0d617780998, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b99368861fc, moduleTitle=Actelion肺动脉高压药物Uptravi获欧盟批准，扩大适应症范围, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b99368861fc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1589956, encodeId=a1971589956f0, content=<a href='/topic/show?id=2d1c63118e9' target=_blank style='color:#2F92EE;'>#欧盟批准#</a>, objectTitle=欧盟批准武田外科手术贴片TachoSil（人凝血酶/人纤维蛋白原）用于神经外科手术, objectType=article, longId=67292, objectId=25c16e29269, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=25c16e29269, replyNumber=0, likeNumber=27, createdTime=2016-04-30, rootId=0, userName=chenwq14, userId=f0d617780998, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=25c16e29269, moduleTitle=欧盟批准武田外科手术贴片TachoSil（人凝血酶/人纤维蛋白原）用于神经外科手术, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=25c16e29269)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1589955, encodeId=bdb01589955ef, content=<a href='/topic/show?id=2d1c63118e9' target=_blank style='color:#2F92EE;'>#欧盟批准#</a>, objectTitle=PD-1免疫疗法监管重大里程碑：百时美Opdivo获欧盟批准，系欧洲PD-1疗法, objectType=article, longId=52397, objectId=b2135239e88, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b2135239e88, replyNumber=0, likeNumber=56, createdTime=2015-06-25, rootId=0, userName=chenwq14, userId=f0d617780998, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b2135239e88, moduleTitle=PD-1免疫疗法监管重大里程碑：百时美Opdivo获欧盟批准，系欧洲PD-1疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b2135239e88)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1589954, encodeId=48ab158995469, content=<a href='/topic/show?id=2d1c63118e9' target=_blank style='color:#2F92EE;'>#欧盟批准#</a>, objectTitle=里程碑！欧盟批准罗氏安维汀（Avastin）联合化疗治疗晚期宫颈癌, objectType=article, longId=49147, objectId=a38a4914ee9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a38a4914ee9, replyNumber=0, likeNumber=70, createdTime=2015-04-10, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a38a4914ee9, moduleTitle=里程碑！欧盟批准罗氏安维汀（Avastin）联合化疗治疗晚期宫颈癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a38a4914ee9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1589953, encodeId=fa2915899534f, content=<a href='/topic/show?id=2d1c63118e9' target=_blank style='color:#2F92EE;'>#欧盟批准#</a>, objectTitle=Orexigen口服减肥药Mysimba获欧盟批准, objectType=article, longId=48801, objectId=870548801f1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=870548801f1, replyNumber=0, likeNumber=60, createdTime=2015-04-01, rootId=0, userName=chenwq14, userId=f0d617780998, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=870548801f1, moduleTitle=Orexigen口服减肥药Mysimba获欧盟批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=870548801f1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1589952, encodeId=3859158995299, content=<a href='/topic/show?id=2d1c63118e9' target=_blank style='color:#2F92EE;'>#欧盟批准#</a>, objectTitle=欧盟批准辉瑞肺炎疫苗Prevenar 13（沛儿13）用于18岁及以上成人群体, objectType=article, longId=47856, objectId=6b964e8560c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6b964e8560c, replyNumber=0, likeNumber=0, createdTime=2015-03-08, rootId=0, userName=chenwq14, userId=f0d617780998, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6b964e8560c, moduleTitle=欧盟批准辉瑞肺炎疫苗Prevenar 13（沛儿13）用于18岁及以上成人群体, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6b964e8560c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1589951, encodeId=3ff01589951f1, content=<a href='/topic/show?id=2d1c63118e9' target=_blank style='color:#2F92EE;'>#欧盟批准#</a>, objectTitle=后生可畏，拜耳眼科药物Eylea第4个适应症获欧盟批准, objectType=article, longId=47529, objectId=cb1f4e529ab, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cb1f4e529ab, replyNumber=0, likeNumber=81, createdTime=2015-03-02, rootId=0, userName=chenwq14, userId=f0d617780998, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cb1f4e529ab, moduleTitle=后生可畏，拜耳眼科药物Eylea第4个适应症获欧盟批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cb1f4e529ab)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1589950, encodeId=8441158995014, content=<a href='/topic/show?id=2d1c63118e9' target=_blank style='color:#2F92EE;'>#欧盟批准#</a>, objectTitle=里程碑！西方世界干细胞治疗产品Holoclar获欧盟批准, objectType=article, longId=47497, objectId=1ace4e49771, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1ace4e49771, replyNumber=0, likeNumber=0, createdTime=2015-03-01, rootId=0, userName=chenwq14, userId=f0d617780998, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1ace4e49771, moduleTitle=里程碑！西方世界干细胞治疗产品Holoclar获欧盟批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1ace4e49771)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

欧盟批准

2020-05-29

chenwq14 (审核中...)

前往app查看评论内容

#欧盟批准#

丙肝重大里程碑！吉利德全球泛基因型丙肝鸡尾酒Epclusa获美国和欧盟批准！

2016-07-12

chenwq14 (审核中...)

前往app查看评论内容

#欧盟批准#

欧盟批准武田抗癌药Adcetris用于霍奇金淋巴瘤患者干细胞移植后的巩固治疗

2016-07-09

chenwq14 (审核中...)

前往app查看评论内容

#欧盟批准#

喜讯！百健和艾伯维每月一次皮下注射多发性硬化症药物Zinbryta获欧盟批准

2016-07-09

chenwq14 (审核中...)

前往app查看评论内容

#欧盟批准#

第6个适应症！欧盟批准强生重磅抗炎药Simponi治疗多关节型幼年特发性关节炎（pJIA）

2016-07-05

chenwq14 (审核中...)

前往app查看评论内容

#欧盟批准#

喜讯！欧盟批准阿斯利康新型抗生素Zavicefta（CAZ-AVI），治疗严重细菌性感染

2016-07-01

chenwq14 (审核中...)

前往app查看评论内容

#欧盟批准#

诺华Afinitor获欧盟批准治疗非功能性胃肠道和肺部神经内分泌肿瘤（NET）

2016-06-07

chenwq14 (审核中...)

前往app查看评论内容

#欧盟批准#

第5个适应症！欧盟批准艾伯维突破性抗癌药Imbruvica一线治疗慢性淋巴细胞白血病（CLL）

2016-06-07

chenwq14 (审核中...)

前往app查看评论内容

#欧盟批准#

葛兰素史克用于治疗儿童免疫疾病的基因药获欧盟批准

2016-06-07

chenwq14 (审核中...)

前往app查看评论内容

#欧盟批准#

基因治疗领域里程碑事件：欧盟批准制药巨头GSK的基因疗法上市

2016-06-07

chenwq14 (审核中...)

前往app查看评论内容

#欧盟批准#

基因治疗新篇章！葛兰素史克干细胞基因疗法Strimvelis获欧盟批准治疗ADA-SCID

2016-06-07

chenwq14 (审核中...)

前往app查看评论内容

#欧盟批准#

多发性骨髓瘤药物daratumumab获欧盟批准

2016-05-30

chenwq14 (审核中...)

前往app查看评论内容

#欧盟批准#

百健/Sobi长效B型血液病新药Alprolix（rFIXFc）获欧盟批准

2016-05-23

chenwq14 (审核中...)

前往app查看评论内容

#欧盟批准#

Actelion肺动脉高压药物Uptravi获欧盟批准，扩大适应症范围

2016-05-23

chenwq14 (审核中...)

前往app查看评论内容

#欧盟批准#

欧盟批准武田外科手术贴片TachoSil（人凝血酶/人纤维蛋白原）用于神经外科手术

2016-04-30

chenwq14 (审核中...)

前往app查看评论内容

#欧盟批准#

PD-1免疫疗法监管重大里程碑：百时美Opdivo获欧盟批准，系欧洲PD-1疗法

2015-06-25

仁医06 (审核中...)

前往app查看评论内容

#欧盟批准#

里程碑！欧盟批准罗氏安维汀（Avastin）联合化疗治疗晚期宫颈癌

2015-04-10

chenwq14 (审核中...)

前往app查看评论内容

#欧盟批准#

Orexigen口服减肥药Mysimba获欧盟批准

2015-04-01

chenwq14 (审核中...)

前往app查看评论内容

#欧盟批准#

欧盟批准辉瑞肺炎疫苗Prevenar 13（沛儿13）用于18岁及以上成人群体

2015-03-08

chenwq14 (审核中...)

前往app查看评论内容

#欧盟批准#

后生可畏，拜耳眼科药物Eylea第4个适应症获欧盟批准

2015-03-02

chenwq14 (审核中...)

前往app查看评论内容

#欧盟批准#

里程碑！西方世界干细胞治疗产品Holoclar获欧盟批准

2015-03-01

科室
- - 订阅+
  - 更多科室
工具
服务